Welcome to our dedicated page for Orchestra BioMed Holdings news (Ticker: OBIO), a resource for investors and traders seeking the latest updates and insights on Orchestra BioMed Holdings stock.
Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO) generates news primarily around its cardiovascular device programs, strategic partnerships and capital markets activity. The company describes itself as a biomedical innovation platform that advances high-impact technologies to patients through collaborations and risk-reward sharing agreements with global medical device companies, which often leads to announcements of new agreements, trial milestones and financial transactions.
News coverage for Orchestra BioMed frequently highlights progress in its two flagship product candidates: Atrioventricular Interval Modulation (AVIM) Therapy for hypertension and the Virtue Sirolimus AngioInfusion Balloon (Virtue SAB) for atherosclerotic artery disease. Investors can expect updates on pivotal clinical trials such as the BACKBEAT global study for AVIM Therapy and the Virtue Trial, a U.S. IDE pivotal trial comparing Virtue SAB to a commercially available paclitaxel-coated balloon in coronary in-stent restenosis.
The company’s releases also detail strategic collaborations and rights agreements, including its partnership with Medtronic for AVIM Therapy and a right of first refusal arrangement with Terumo related to Virtue SAB for coronary artery disease. Additional news items describe revenue participation and financing agreements with partners such as Ligand Pharmaceuticals, as well as public offerings, private placements and preferred stock issuances that support its clinical programs.
On this OBIO news page, readers can review company press releases, third-party announcements referencing Orchestra BioMed and regulatory-related communications. Topics typically include clinical data presentations, conference participation, updates on FDA Breakthrough Device Designation status for AVIM Therapy and Virtue SAB, and disclosures of material agreements filed via Form 8-K. Investors and researchers who follow developments in device-based hypertension therapy and drug-delivery balloons for coronary and peripheral artery disease may find this news feed particularly relevant.
Orchestra BioMed (Nasdaq: OBIO) received a $15 million tranche from Ligand under a previously announced royalty purchase agreement, completing a scheduled payment and bringing Ligand capital to $40 million to date. The financing grants Ligand a tiered royalty interest in Orchestra BioMed’s future revenue.
Proceeds will fund ongoing randomized pivotal trials for AVIM Therapy and Virtue SAB. Together with a separate $20 million Medtronic investment, Orchestra reported $35 million in fresh strategic capital received on May 1, 2026.
Orchestra BioMed (NASDAQ: OBIO) received a $20 million payment from Medtronic on May 1, 2026, fulfilling a scheduled tranche under their strategic financing agreement and supporting completion of the BACKBEAT Global Pivotal Trial for AVIM Therapy.
Together with a $15 million tranche from Ligand, the company received $35 million in strategic capital; the Medtronic funds were issued as a secured subordinated promissory note convertible to a capped prepaid revenue share tied to FDA approval, with crediting at a low double-digit percentage up to $40 million cumulative.
Orchestra BioMed (Nasdaq: OBIO) announced the FDA granted a second Breakthrough Device Designation for AVIM Therapy on April 30, 2026, expanding indications to patients with uncontrolled hypertension despite medication and a pacemaker indication. The designations cover an addressable U.S. population of over 7.7 million adults and may support NTAP and Transitional Pass-Through reimbursement. Orchestra BioMed is conducting the BACKBEAT Global Pivotal Trial with Medtronic to evaluate AVIM in pacemaker-indicated patients.
Orchestra BioMed (NASDAQ: OBIO) announced presentations at HRS 2026 detailing AVIM Therapy clinical and mechanistic data from MODERATO II and a pressure-volume study. Key findings: immediate mean oSBP reduction of 13.2 mmHg, 97% of patients had >5 mmHg oSBP drop, 6-month mean aSBP 125.2 mmHg, and sustained aSBP reductions through 3.6 years in a sub-cohort. Orchestra is enrolling the BACKBEAT Global Pivotal Trial in collaboration with Medtronic (MDT).
Orchestra BioMed (Nasdaq: OBIO) reported full year 2025 results and a Q4 update highlighting a $106.5 million cash and marketable securities position as of December 31, 2025, plus expected proceeds of $35.0 million from Medtronic and Ligand in Q2 2026 and up to $10.7 million from Haemonetics in 2026.
2025 revenue was $33.5 million (primarily non-recurring related to Terumo arrangements). R&D rose to $58.2 million; net loss narrowed to $52.7 million or ($1.11) per share. Backbeat and Virtue pivotal trials are underway with accelerated BACKBEAT enrollment after Q4 protocol amendments.
Orchestra BioMed (Nasdaq: OBIO) announced two conference presentations at THT (Mar 3, 2026) and CRT (Mar 8, 2026) on AVIM Therapy, a pacemaker-based approach for hypertension, diastolic dysfunction and heart failure.
Presenters will share pilot data showing sustained systolic blood pressure reductions, improved hemodynamics, ventricular remodeling, and ongoing BACKBEAT pivotal study progress.
Orchestra BioMed (Nasdaq: OBIO) said management will attend two institutional investor conferences in March 2026: TD Cowen (March 2-4) and Barclays Global Healthcare (March 10-12). Fireside chats are scheduled for March 3 at 9:50am ET and March 11 at 8:00am ET, with webcasts available live and archived on the company’s investor relations site.
Orchestra BioMed (Nasdaq: OBIO) announced that on February 12, 2026 its Compensation Committee granted stock options for an aggregate of 120,000 shares to nine newly hired employees under the 2025 New Hire Inducement Plan.
The options vest over a four-year period and were issued as inducement awards in accordance with Nasdaq Listing Rule 5635(c)(4).
Orchestra BioMed (NASDAQ: OBIO) expects to receive up to $21 million in cash proceeds from the sale of its strategic holding Vivasure to Haemonetics, which closed on January 9, 2026. Orchestra expects $11 million in 2026 (approximately $5 million upfront and ~$6 million milestone) with the remainder payable via future revenue earnouts tied to milestones. Vivasure’s PerQseal Elite is CE marked for arterial and venous indications, has a PMA filed with the FDA in 2025, and reported 0% major complications at 30 days in the ELITE arterial study.
Vivasure Medical was acquired by Haemonetics (NYSE: HAE) in a transaction valued up to €185M (~$215M) payable on completion of certain milestones. Vivasure, based in Galway, develops fully absorbable polymer implants and delivery systems for minimally invasive arterial and venous vessel closure. Vivasure previously received an expanded CE mark for PerQseal Elite covering large-bore venous closure and has submitted a PMA application to the FDA for PerQseal Elite for arterial procedures. Haemonetics made a strategic investment in Vivasure in 2022 that included an acquisition option. PerQseal products are not currently available for sale in the United States.